IMI Trials@Home

›𝗪𝗵𝗮𝘁 𝗛𝗮𝗽𝗽𝗲𝗻𝗲𝗱 𝗶𝗻 𝗣𝗮𝗿𝗶𝘀? 🗼  𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗧𝗿𝗶𝗮𝗹𝘀@𝗛𝗼𝗺𝗲 𝗔𝗻𝗻𝘂𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝟮𝟬𝟮𝟰 Earlier this month, we gathered in Paris for the Trials@Home Annual Meeting, hosted graciously by 𝗡𝗮𝘁𝗮𝗹𝗶𝗲 𝗣𝗶𝘁𝗼𝗻, 𝗛𝗲𝗮𝗱 𝗼𝗳 𝗣𝘂𝗯𝗹𝗶𝗰-𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀 𝗮𝘁 𝗦𝗮𝗻𝗼𝗳𝗶, at the Sanofi Paris-Gentilly offices. A big thank-you to Sanofi for making us feel so welcome during this insightful three-day event! 𝗗𝗮𝘆𝘀 𝟭 & 𝟮 The first two days were packed with working sessions and project updates from our consortium members, both in-person and online. We reflected on key deliverables and milestones achieved in the past year and explored what lies ahead. Our project leads Kim Hawkins and Mira Zuidgeest perfectly summarized it in three key words: 𝗮𝗰𝗰𝗼𝗺𝗽𝗹𝗶𝘀𝗵𝗺𝗲𝗻𝘁𝘀, 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻, 𝗮𝗻𝗱 𝗿𝗲𝗰𝗼𝗺𝗺𝗲𝗻𝗱𝗮𝘁𝗶𝗼𝗻𝘀. A highlight of Day 2 was a virtual guest appearance by Dr. Leonard Sacks, Acting Deputy Director of the FDA’s Office of Medical Policy, who clarified the FDA’s new guidelines for decentralized clinical trial (DCT) approaches—a critical discussion for our consortium’s work. 𝗗𝗮𝘆 𝟯: 𝗙𝗼𝗰𝘂𝘀 𝗼𝗻 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 The final day opened with Paloma Mallorquin from Innovative Health Initiative (IHI), who shared IHI’s expectations for delivering impactful, sustainable outcomes as a public-private partnership. Paloma emphasized that effective communication is crucial for showcasing our work to external stakeholders and reaffirmed the value of public private partnerships, noting the consortium’s excellent progress so far. We also welcomed Rod Junor and Joachim Lövin from TransCelerate BioPharma Inc., who provided updates on TransCelerate’s work around site and patient preferences in DCTs. Their session led into an engaging panel discussion on the future of DCTs, moderated by Isla Mackenzie. Panelists, including Joao Nabais, 𝗧𝗶𝗳𝗳𝗮𝗻𝘆 𝗧𝘀𝗮𝗰𝗵𝗮𝗹𝗶𝗻𝗮, 𝗝𝗼𝗮𝗰𝗵𝗶𝗺 𝗟𝗼𝘃𝗶𝗻, 𝗮𝗻𝗱 𝗥𝗼𝗱 𝗝𝘂𝗻𝗼𝗿, debated whether we’re placing too much burden on sites and patients—an important topic for the field. Finally, we wrapped up with a Q&A panel on RADIAL, featuring Mira Zuidgeest, Helga Gardarsdottir, Yvonne van Rijswick, Bart Lagerwaard, Sten Hanke, 𝗧𝗵𝗲𝗿𝗲𝘀𝗮 𝗪𝗲𝗶𝘁𝗹𝗮𝗻𝗲𝗿, and Megan Heath. They shared challenges and insights gained from their work on our proof-of-concept study RADIAL, offering valuable insights for the consortium moving forward. Before concluding, we celebrated the season with a trip to a Christmas market in Paris—a perfect end to a productive meeting! 𝗦𝘁𝗮𝘆 𝘁𝘂𝗻𝗲𝗱 𝗮𝘀 𝘄𝗲 𝗺𝗼𝘃𝗲 𝗶𝗻𝘁𝗼 𝗮𝗻 𝗲𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝘆𝗲𝗮𝗿 𝗮𝗵𝗲𝗮𝗱.

Last week, we gathered in Paris for the fifth annual meeting of the IMI Trials@Home project. It was a wonderful opportunity to reconnect with enthusiastic colleagues, reflect on our journey, and celebrate how far we’ve come. When we began in 2019, we couldn’t have imagined the incredible path this project would take. It’s truly inspiring to see the insights we’ve gained about decentralised clinical trials (DCTs) — from understanding facilitators and barriers of their conduct to exploring stakeholder acceptance. As we move into the final year of this journey, I’m excited to collaborate with the IMI Trials@Home team to share these key learnings with the wider community. For more information about IMI Trials@Home and our publications, visit our website: https://trialsathome.com/ #DecentralisedClinicalTrials #DCT #IMITrialsAtHome #ClinicalResearch 

🏠 IMI Trials@Home aims to reshape clinical trial design and move them to an at home setting.   🔎 As part of the project, IDF Europe oversees a #patient engagement panel (PEP) consisting of people living with lived experience of #diabetes. The PEP was involved in every stage of the research project.   💡 With the project nearing completion, we want to reflect on this #engagement. Guidelines on the topic of lived experience engagement often lack a strong reflective element that allows for impact #evaluation that includes both lived experience participants and #researchers.   👉 We have therefore started an evaluation of the #PEP engagement, based both on the perspectives of the consortium members who interacted with the PEP and from the PEP itself. This will provide a knowledge base for #involvement of people with lived experience in large-multi-partner consortium projects such as Trials@Home! 🙌 Follow IMI Trials@Home to stay up to date on the project’s progress!   ➡️ Read more about Trials@Home here: https://lnkd.in/ef_WVMhN ________________________________________________________________ Sabine Dupont | Erik Werson | Kostas Tagkalos | Ken Tait | Joao Nabais | Cameron Keighron | Joachim Lövin

💡 What drives people's decision to take part in a clinical trial from home? 💡 We are excited to share that our latest research on this topic has been published in the Journal Clinical and Translational Science. In our paper, titled ‘What motivates people with type 2 diabetes mellitus to participate in clinical trials from home?’, we investigate the drivers and perceptions when people decide whether to take part in clinical trials with different levels of decentralisation. This is especially important to design future clinical trials that are more patient centric and less burdensome for participants. I am incredibly grateful for the support of everyone who contributed to this project. A special thanks to my supervisors, co-authors and collaborators. Thank you Bart Lagerwaard, Magdalena Beran, Jorien Veldwijk, Julia Mader, Tina Pöttler, Dietrich Tews, Diederick (Rick) E. Grobbee, MD, PhD, FESC and Mira Zuidgeest. You can read the full article here: https://lnkd.in/e2jCTCNG IMI Trials@Home #decentralisedclinicaltrials #trialsathome #driversfortrialparticipation #ASCPTJournalFamily #CTSJournal

This week, I had the opportunity to present the interim results of our research on preferences for participation in clinical trials with different decentralization levels at the #ISPOREurope conference in Barcelona. Many thanks to everyone who took the time to stop by the poster. You can read our abstract here: https://lnkd.in/eipNCPJ3 IMI Trials@Home #ISPOREurope #decentralisedclinicaltrials #patientpreferences #discretechoiceexperiment 

If you're interested in the results, the poster is now available at the project website -> https://lnkd.in/eMwf2TKs We'll let you know when the final results are available!

🌍 Happy #WorldDiabetesDay! At the heart of the Trials@Home project are the patients themselves. Our dedicated Patient Expert Panel (PEP), which includes individuals living with diabetes and is led by International Diabetes Federation Europe, has played an essential role throughout the development of our RADIAL study. They’ve also contributed by translating scientific papers into accessible language and developing educational materials for both patients and patient advocates on the fundamentals of Decentralized Clinical Trials (DCTs). Thank you PEP members!! In addition, we’ve conducted research within the diabetes community to better understand their preferences and the trade-offs involved in participating in clinical trials with decentralized elements. We explored various scenarios across three countries. We’re excited to share that the interim findings from the first country, the Netherlands, will be presented in a poster session at ISPOR in Barcelona on November 18th, by Julia Kopanz (UMCU), who led the research.

On Monday 18 November, Julia Kopanz (UMCU) will present her poster “𝘿𝙤 𝙋𝙚𝙤𝙥𝙡𝙚 𝙋𝙧𝙚𝙛𝙚𝙧 𝙩𝙤 𝙋𝙖𝙧𝙩𝙞𝙘𝙞𝙥𝙖𝙩𝙚 𝙞𝙣 𝙖 𝘾𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝙏𝙧𝙞𝙖𝙡 𝙁𝙧𝙤𝙢 𝙃𝙤𝙢𝙚? 𝘼 𝘿𝙞𝙨𝙘𝙧𝙚𝙩𝙚 𝘾𝙝𝙤𝙞𝙘𝙚 𝙀𝙭𝙥𝙚𝙧𝙞𝙢𝙚𝙣𝙩 𝙞𝙣 𝙋𝙚𝙧𝙨𝙤𝙣𝙨 𝙇𝙞𝙫𝙞𝙣𝙜 𝙒𝙞𝙩𝙝 𝙏𝙮𝙥𝙚 2 𝘿𝙞𝙖𝙗𝙚𝙩𝙚𝙨 𝙈𝙚𝙡𝙡𝙞𝙩𝙪𝙨” with the interim results of her research at ISPOR—The Professional Society for Health Economics and Outcomes Research Europe in Barcelona (poster session 2) Interested in knowing more about this topic? Julia will be happy to answer all your questions during the session! More info here: https://lnkd.in/e_pcu2CE

Thank you Katie Baca-Motes for having me and Cristina Ortega Duran in the panel. It was great to talk to you about the experiences from IMI Trials@Home on trials with decentralised elements!

It has been a true pleasure to have Amos de Jong as part of our consortium! Congratulations Dr!